Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 2/20 | 0.67 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.50 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.50 |
| ▸ | AKR1C4 | P17516 | 2/20 | 0.50 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.50 |
| ▸ | TPMT | P51580 | 2/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.46 |
| ▸ | CA12 | O43570 | 3/20 | 0.43 |
| ▸ | CA1 | P00915 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | CA7 | P43166 | 3/20 | 0.43 |
| ▸ | CA9 | Q16790 | 3/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.43 |
| ▸ | CA3 | P07451 | 2/20 | 0.43 |
| ▸ | CA4 | P22748 | 2/20 | 0.43 |
| ▸ | CA6 | P23280 | 2/20 | 0.43 |
| ▸ | CA5A | P35218 | 2/20 | 0.43 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13449170 | 0.88 | TTR (0.48) | TTRAKR1C3AKR1C2AKR1C4AKR1C1 | |
| SCHEMBL21545149 | 0.82 | TTR (0.58) | TTRAKR1C3AKR1C2AKR1C4AKR1C1 | |
| SCHEMBL21438414 | 0.82 | TTR (0.58) | TTRAKR1C3AKR1C2AKR1C4AKR1C1 | |
| SCHEMBL28515652 | 0.82 | TTR (0.58) | TTRAKR1C3AKR1C2AKR1C4AKR1C1 | |
| SCHEMBL1114408 | 0.81 | TTR (1.00) | TTRAKR1C3AKR1C2AKR1C4AKR1C1 | |
| SCHEMBL27361398 | 0.81 | TTR (0.50) | TTRAKR1C3AKR1C2TPMTCA12 | |
| SCHEMBL12724992 | 0.80 | TTR (0.41) | TTRAKR1C3AKR1C2AKR1C4AKR1C1 | |
| SCHEMBL1639428 | 0.80 | KDM4E (0.52) | TTRTPMTPTPN1CA12CA1 | |
| SCHEMBL13449165 | 0.80 | LMNA (0.42) | TTRAKR1C3AKR1C2AKR1C4AKR1C1 | |
| SCHEMBL6969296 | 0.78 | HMGB1 (0.47) | TTRAKR1C3AKR1C2TPMTCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9718800-B2 | Chromenone derivatives | ASTRAZENECA AB (SE) | 2017-08-01 | — | — | US | disclosed |
| US-9718800-B2 | Chromenone derivatives | ASTRAZENECA AB (SE) | 2017-08-01 | — | — | US | disclosed |
| US-9718800-B2 | Chromenone derivatives | ASTRAZENECA AB (SE) | 2017-08-01 | — | — | US | disclosed |
| US-20160272607-A1 | CHROMENONE DERIVATIVES | ASTRAZENECA AB (SE) | 2016-09-22 | — | — | US | disclosed |
| US-20160272607-A1 | CHROMENONE DERIVATIVES | ASTRAZENECA AB (SE) | 2016-09-22 | — | — | US | disclosed |
| US-20160272607-A1 | CHROMENONE DERIVATIVES | ASTRAZENECA AB (SE) | 2016-09-22 | — | — | US | disclosed |
| US-20160060240-A1 | CHROMENONE DERIVATIVES | ASTRAZENECA AB (SE) | 2016-03-03 | — | — | US | disclosed |
| US-20160060240-A1 | CHROMENONE DERIVATIVES | ASTRAZENECA AB (SE) | 2016-03-03 | — | — | US | disclosed |
| US-20160060240-A1 | CHROMENONE DERIVATIVES | ASTRAZENECA AB (SE) | 2016-03-03 | — | — | US | disclosed |
| EP-2697220-B1 | CHROMENONE COMPOUNDS AS PI 3-KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2016-01-13 | — | — | EP | disclosed |
| US-20120264731-A1 | CHROMENONE DERIVATIVES | ASTRAZENECA AB (SE) | 2012-10-18 | — | — | US | disclosed |
| WO-2012140419-A1 | CHROMENONE COMPOUNDS AS PI 3 -KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2012-10-18 | — | — | WO | disclosed |
| US-20120264731-A1 | CHROMENONE DERIVATIVES | ASTRAZENECA AB (SE) | 2012-10-18 | — | — | US | disclosed |
| CN-102712615-A | Chromenone Derivatives with Antitumor Activity | ASTRAZENECA AB | 2012-10-03 | — | — | CN | disclosed |
| EP-2493870-A1 | CHROMENONE DERIVATIVES WITH ANTI-TUMOUR ACTIVITY | AstraZeneca AB (SE) | 2012-09-05 | — | — | EP | disclosed |
| WO-2011051704-A1 | CHROMENONE DERIVATIVES WITH ANTI-TUMOUR ACTIVITY | ASTRAZENECA AB (SE) | 2011-05-05 | — | — | WO | disclosed |
| WO-2011051704-A1 | CHROMENONE DERIVATIVES WITH ANTI-TUMOUR ACTIVITY | ASTRAZENECA AB (SE) | 2011-05-05 | — | — | WO | disclosed |
| US-20110098271-A1 | CHROMENONE DERIVATIVES | ASTRAZENECA AB (SE) | 2011-04-28 | — | — | US | disclosed |
| US-20110098271-A1 | CHROMENONE DERIVATIVES | ASTRAZENECA AB (SE) | 2011-04-28 | — | — | US | disclosed |
| US-20110098271-A1 | CHROMENONE DERIVATIVES | ASTRAZENECA AB (SE) | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098271-A1 | CHROMENONE DERIVATIVES | RB1, CYP11B1, CCND3 | TTR 2584/4885AKR1C3 75/4885AKR1C2 199/4885 |
| US-20160272607-A1 | CHROMENONE DERIVATIVES | RB1, CYP11B1, CCND3 | TTR 2584/4885AKR1C3 75/4885AKR1C2 199/4885 |
| US-20120264731-A1 | CHROMENONE DERIVATIVES | RB1, CYP11B1, CCND1 | TTR 1998/4885AKR1C3 79/4885AKR1C2 175/4885 |
| US-20160060240-A1 | CHROMENONE DERIVATIVES | RB1, CYP11B1, CCND3 | TTR 2584/4885AKR1C3 75/4885AKR1C2 199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.